{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:50:12Z","timestamp":1786978212101,"version":"build-2736575974"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Progressive cerebellar ataxias, including the polyglutamine spinocerebellar ataxias (SCA1, SCA2, SCA3, and SCA6), Friedreich ataxia, and the autosomal recessive and sporadic forms, are rare, clinically heterogeneous neurodegenerative disorders. Disease-modifying therapies, notably antisense oligonucleotides and the approved compound omaveloxolone, are now entering or reaching the clinic, which makes reliable prediction of disease progression a central obstacle to trial success. Rarity, slow and variable decline, and a quantifiable premanifest window together demand sensitive, validated tools to forecast who will progress, how fast, and when symptoms begin. This review synthesizes evidence across five complementary biomarker domains, clinical, imaging, fluid, genetic, and digital, and judges their readiness for forecasting onset and progression. Clinical scales such as SARA capture genotype-specific trajectories but lose sensitivity at the extremes of the disease course. Volumetric, microstructural, and spectroscopic MRI and blood neurofilament light chain change before ataxia onset and predict subsequent decline, whereas repeat length and genetic modifiers set prior risk. Wearable-sensor gait and balance metrics detect change earlier than clinical scales and sharply reduce required sample sizes. We argue that no single modality satisfies every context of use, and that stage-specific, multimodal composites, integrated through harmonized international cohorts and machine learning, offer the most credible path to prognostic enrichment and to shorter, adequately powered, and preventive trials.<\/jats:p>","DOI":"10.3389\/fneur.2026.1921210","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:45:21Z","timestamp":1786974321000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting disease progression in progressive cerebellar ataxias: integrating clinical, imaging, fluid, genetic, and digital biomarkers"],"prefix":"10.3389","volume":"17","author":[{"given":"Yingxu","family":"Hao","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital (Brain Disease Center), Henan University of Chinese Medicine","place":["Zhengzhou, Henan, China"]},{"name":"The First Clinical Medical College (College of Integrated Chinese and Western Medicine), Henan University of Chinese Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Hao","sequence":"additional","affiliation":[{"name":"Hebi Coal Industry Group General Hospital","place":["Hebi, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-019-0074-3","article-title":"Spinocerebellar ataxia","volume":"5","author":"Klockgether","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1474-4422(23)00068-6","article-title":"Autosomal dominant cerebellar ataxias: new genes and progress towards treatments","volume":"22","author":"Coarelli","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"104606","DOI":"10.1016\/j.nbd.2019.104606","article-title":"Friedreich ataxia-pathogenesis and implications for therapies","volume":"132","author":"Delatycki","year":"2019","journal-title":"Neurobiol Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000358801","article-title":"The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies","volume":"42","author":"Ruano","year":"2014","journal-title":"Neuroepidemiology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-019-0372-4","article-title":"Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia","volume":"51","author":"Cortese","year":"2019","journal-title":"Nat Genet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1056\/NEJMoa2207406","article-title":"Deep intronic FGF14 GAA repeat expansion in late-onset cerebellar ataxia","volume":"388","author":"Pellerin","year":"2023","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41582-018-0051-6","article-title":"Spinocerebellar ataxias: prospects and challenges for therapy development","volume":"14","author":"Ashizawa","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature22044","article-title":"Antisense oligonucleotide therapy for spinocerebellar ataxia type 2","volume":"544","author":"Scoles","year":"2017","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ana.25264","article-title":"Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice","volume":"84","author":"McLoughlin","year":"2018","journal-title":"Ann Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12311-020-01179-7","article-title":"Antisense oligonucleotide therapy targeted against ATXN3 improves potassium channel-mediated Purkinje neuron dysfunction in spinocerebellar ataxia type 3","volume":"20","author":"Bushart","year":"2021","journal-title":"Cerebellum"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/acn3.51897","article-title":"Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data","volume":"11","author":"Lynch","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40263-024-01113-z","article-title":"New and emerging drug and gene therapies for Friedreich ataxia","volume":"38","author":"Scott","year":"2024","journal-title":"CNS Drugs"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/acn3.51370","article-title":"Spinocerebellar ataxia clinical trials: opportunities and challenges","volume":"8","author":"Brooker","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/14737175.2017.1364628","article-title":"Monitoring disease progression in spinocerebellar ataxias: implications for treatment and clinical research","volume":"17","author":"Sarro","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12311-025-01856-5","article-title":"Biomarkers in spinocerebellar ataxias","volume":"24","author":"Klockgether","year":"2025","journal-title":"Cerebellum"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3390\/ijms27020881","article-title":"Hereditary ataxias: from pathogenesis and clinical features to neuroimaging, fluid, and digital biomarkers: a scoping review","volume":"27","author":"Bernardi","year":"2026","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1474-4422(20)30235-0","article-title":"Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study","volume":"19","author":"Jacobi","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/acn3.51118","article-title":"Test-retest reliability of the Friedreich's ataxia rating scale","volume":"7","author":"Rummey","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1212\/WNL.0b013e31822e7ca0","article-title":"The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study","volume":"77","author":"Jacobi","year":"2011","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","article-title":"Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study","volume":"14","author":"Jacobi","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e1499","DOI":"10.1212\/WNL.0000000000200913","article-title":"Natural history of Friedreich ataxia: heterogeneity of neurologic progression and consequences for clinical trial design","volume":"99","author":"Rummey","year":"2022","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1007\/s00415-024-12475-1","article-title":"SARA captures disparate progression and responsiveness in spinocerebellar ataxias","volume":"271","author":"Petit","year":"2024","journal-title":"J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1007\/s00415-018-8954-0","article-title":"Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias","volume":"265","author":"Jacobi","year":"2018","journal-title":"J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s12311-024-01657-2","article-title":"Factors influencing health-related quality of life of patients with spinocerebellar ataxia","volume":"23","author":"Weber","year":"2024","journal-title":"Cerebellum"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00415-025-13024-0","article-title":"Longitudinal description of health-related quality of life and depressive symptoms in polyQ spinocerebellar ataxia patients","volume":"272","author":"Iskandar","year":"2025","journal-title":"J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/brain\/awx317","article-title":"The cerebellar cognitive affective\/Schmahmann syndrome scale","volume":"141","author":"Hoche","year":"2018","journal-title":"Brain"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinph.2021.12.005","article-title":"Neurophysiological features in spinocerebellar ataxia type 2: prospects for novel biomarkers","volume":"135","author":"Vel\u00e1zquez-P\u00e9rez","year":"2022","journal-title":"Clin Neurophysiol"},{"key":"ref29","first-page":"924","article-title":"Consensus recommendations for clinical outcome assessments and registry development in ataxias: Ataxia global initiative (AGI) working group expert guidance","volume-title":"Cerebellum","author":"Klockgether","year":"2023"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12311-025-01885-0","article-title":"The natural history study and biomarker collection of the clinical research consortium for the study of cerebellar Ataxia (CRC-SCA)","volume":"24","author":"Lin","year":"2025","journal-title":"Cerebellum"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"677551","DOI":"10.3389\/fneur.2021.677551","article-title":"The ARCA registry: a collaborative global platform for advancing trial readiness in autosomal recessive cerebellar ataxias","volume":"12","author":"Trasch\u00fctz","year":"2021","journal-title":"Front Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/mds.29324","article-title":"Evolution of clinical outcome measures and biomarkers in sporadic adult-onset degenerative ataxia","volume":"38","author":"Oender","year":"2023","journal-title":"Mov Disord"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/mdc3.12804","article-title":"Sensitivity of volumetric magnetic resonance imaging and magnetic resonance spectroscopy to progression of spinocerebellar ataxia type 1","volume":"6","author":"Deelchand","year":"2019","journal-title":"Mov Disord Clin Pract"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"fcaa184","DOI":"10.1093\/braincomms\/fcaa184","article-title":"Brainstem and striatal volume changes are detectable in under 1 year and predict motor decline in spinocerebellar ataxia type 1","volume":"2","author":"Koscik","year":"2020","journal-title":"Brain Commun."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e100905","DOI":"10.1016\/j.landig.2025.100905","article-title":"Development and validation of a composite digital balance score for spinocerebellar ataxia: a prospective study","volume":"7","author":"McNames","year":"2025","journal-title":"Lancet Digit Health"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1002\/acn3.70116","article-title":"Fixel-based analysis of diffusion imaging as a quantitative marker of disease state in spinocerebellar ataxia","volume":"12","author":"Arpin","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1007\/s00415-023-11763-6","article-title":"The longitudinal progression of MRI changes in pre-ataxic carriers of SCA3\/MJD","volume":"270","author":"De Oliveira","year":"2023","journal-title":"J Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/ana.26573","article-title":"Clinically meaningful magnetic resonance endpoints sensitive to preataxic spinocerebellar ataxia types 1 and 3","volume":"93","author":"Chandrasekaran","year":"2023","journal-title":"Ann Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/acn3.504","article-title":"Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2","volume":"5","author":"Reetz","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s12311-024-01674-1","article-title":"Structural brain correlates of sleep microstructure in spinocerebellar ataxia type 2 and its role on clinical phenotype","volume":"23","author":"Rodr\u00edguez-Labrada","year":"2024","journal-title":"Cerebellum"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e209749","DOI":"10.1212\/WNL.0000000000209749","article-title":"Longitudinal changes of clinical, imaging, and fluid biomarkers in preataxic and early ataxic spinocerebellar ataxia type 2 and 7 carriers","volume":"103","author":"Coarelli","year":"2024","journal-title":"Neurology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/mds.27606","article-title":"Longitudinal evaluation of iron concentration and atrophy in the dentate nuclei in Friedreich ataxia","volume":"34","author":"Ward","year":"2019","journal-title":"Mov Disord"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.29261","article-title":"Progressive spinal cord degeneration in Friedreich's ataxia: results from ENIGMA-Ataxia","volume":"38","author":"Rezende","year":"2023","journal-title":"Mov Disord"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"105774","DOI":"10.1016\/j.nbd.2022.105774","article-title":"Altered retinal structure and function in spinocerebellar ataxia type 3","volume":"170","author":"Toulis","year":"2022","journal-title":"Neurobiol Dis"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"106090","DOI":"10.1016\/j.ebiom.2025.106090","article-title":"Brain atrophy staging in spinocerebellar ataxia type 3 for clinical prognosis and trial enrichment","volume":"123","author":"Baumeister","year":"2026","journal-title":"EBioMedicine"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41582-026-01218-7","article-title":"MRI end-points for clinical trials in ataxias: recommendations from the Ataxia global initiative MRI biomarkers working group","volume":"22","author":"\u00d6z","year":"2026","journal-title":"Nat Rev Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/mds.28783","article-title":"Blood neurofilament light chain in genetic ataxia: a meta-analysis","volume":"37","author":"Peng","year":"2022","journal-title":"Mov Disord"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e11803","DOI":"10.15252\/emmm.201911803","article-title":"Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice","volume":"12","author":"Wilke","year":"2020","journal-title":"EMBO Mol Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13024-019-0338-0","article-title":"Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3","volume":"14","author":"Li","year":"2019","journal-title":"Mol Neurodegener"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"105311","DOI":"10.1016\/j.nbd.2021.105311","article-title":"Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia","volume":"153","author":"Coarelli","year":"2021","journal-title":"Neurobiol Dis"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.3390\/ijms26115070","article-title":"Evaluating glial fibrillary acidic protein and neurofilament light as potential biomarkers for spinocerebellar ataxia 7","volume":"26","author":"Hanna Al-Shaikh","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12311-021-01257-4","article-title":"Neurofilament light chain is a biomarker of neurodegeneration in ataxia telangiectasia","volume":"21","author":"Donath","year":"2022","journal-title":"Cerebellum"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/mds.30250","article-title":"Increase of plasma biomarkers in Friedreich\u2019s ataxia: potential insights into disease pathology","volume":"40","author":"Rummey","year":"2025","journal-title":"Mov Disord"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"fcaf331","DOI":"10.1093\/braincomms\/fcaf331","article-title":"Impact of age on neurofilament light chain in Friedreich ataxia: a 1-year longitudinal study","volume":"7","author":"Petrillo","year":"2025","journal-title":"Brain Commun"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00415-020-10274-y","article-title":"PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study","volume":"268","author":"Gonsior","year":"2021","journal-title":"J Neurol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"874768","DOI":"10.3389\/fnins.2022.874768","article-title":"Simultaneous quantification of mitochondrial mature frataxin and extra-mitochondrial frataxin isoform E in Friedreich's ataxia blood","volume":"16","author":"Wang","year":"2022","journal-title":"Front Neurosci"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"107301","DOI":"10.1016\/j.nbd.2026.107301","article-title":"Cognitive impairment in SCA3: a multi-center cohort study with demographic, imaging, and biomarker correlates","volume":"220","author":"Maas","year":"2026","journal-title":"Neurobiol Dis"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ajhg.2022.03.004","article-title":"Genetic modifiers of Huntington disease differentially influence motor and cognitive domains","volume":"109","author":"Lee","year":"2022","journal-title":"Am J Hum Genet"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/brain\/awaf408","article-title":"Predictive models for ataxia progression and conversion in spinocerebellar ataxia type 1 and 3","volume":"149","author":"Petit","year":"2026","journal-title":"Brain"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1002\/mds.28740","article-title":"Gait variability in spinocerebellar ataxia assessed using wearable inertial sensors","volume":"36","author":"Shah","year":"2021","journal-title":"Mov Disord"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/mds.29757","article-title":"Digital gait measures capture 1-year progression in early-stage spinocerebellar ataxia type 2","volume":"39","author":"Seemann","year":"2024","journal-title":"Mov Disord"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e1199","DOI":"10.1212\/WNL.0000000000010176","article-title":"Real-life gait assessment in degenerative cerebellar ataxia: toward ecologically valid biomarkers","volume":"95","author":"Ilg","year":"2020","journal-title":"Neurology"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1342965","DOI":"10.3389\/fphar.2024.1342965","article-title":"Accelerometer-based measures in Friedreich ataxia: a longitudinal study on real-life activity","volume":"15","author":"Fichera","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1212\/WNL.0000000000009776","article-title":"Features of speech and swallowing dysfunction in pre-ataxic spinocerebellar ataxia type 2","volume":"95","author":"Vogel","year":"2020","journal-title":"Neurology"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e209887","DOI":"10.1212\/WNL.0000000000209887","article-title":"Patient-relevant digital-motor outcomes for clinical trials in hereditary spastic paraplegia type 7: a multicenter PROSPAX study","volume":"103","author":"Beichert","year":"2024","journal-title":"Neurology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1093\/brain\/awad157","article-title":"GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response","volume":"146","author":"Wilke","year":"2023","journal-title":"Brain"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"e70488","DOI":"10.1111\/ene.70488","article-title":"Novel clinical insights from a Swedish RFC1 spectrum disorder cohort","volume":"33","author":"Alm","year":"2026","journal-title":"Eur J Neurol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/brain\/awab363","article-title":"Repeat conformation heterogeneity in cerebellar ataxia, neuropathy, vestibular areflexia syndrome","volume":"145","author":"Miyatake","year":"2022","journal-title":"Brain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1921210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:45:22Z","timestamp":1786974322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1921210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":69,"alternative-id":["10.3389\/fneur.2026.1921210"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1921210","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1921210"}}